Cleveland Story

<div class='circular--portrait' style='background:#008000;color: #FFE4E1;font-size:4em;'>CB</div>
CBLI -- USA Stock  

USD 4.73  0.30  5.96%

Whilst many millenniums are getting more into healthcare space, it makes sense to concentrate on Cleveland Biolabs. We will evaluate why we are still confident in anticipation of a recovery. Is Cleveland Biolabs valuation justified? I am going to cover the firm perspective on valuation to give you a better outlook on taking a position in it.
Published over two weeks ago
View all stories for Cleveland Biolabs | View All Stories
Ready to invest in Cleveland Biolabs now and sell it next quarter?
The current Long Term Debt to Equity is estimated to decrease to 0.0138. The current Debt to Equity Ratio is estimated to decrease to -0.11This firm has a current ratio of 7.45, suggesting that it is liquid enough and is able to pay its financial obligations when due.
We provide trade advice to complement the prevailing expert consensus on Cleveland Biolabs. Our dynamic recommendation engine uses a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
We determine the current worth of Cleveland Biolabs using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Cleveland Biolabs based exclusively on its fundamental and basic technical indicators. By analyzing Cleveland Biolabs's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Cleveland Biolabs's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Cleveland Biolabs. We calculate exposure to Cleveland Biolabs's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Cleveland Biolabs's related companies.

Cleveland Biolabs Investment Alerts

Cleveland investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Cleveland Biolabs performance across your portfolios.Please check all investment alerts for Cleveland

Cleveland Biolabs Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Cleveland value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cleveland Biolabs competition to find correlations between indicators driving the intrinsic value of Cleveland.

How Cleveland utilizes its cash?

To perform a cash flow analysis of Cleveland Biolabs, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Cleveland Biolabs is receiving and how much cash it distributes out in a given period. The Cleveland Biolabs cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Cleveland Biolabs Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (2.37 Million)

Cleveland Biolabs exotic insider transaction detected

Legal trades by Cleveland Biolabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland insider trading alert for general transaction of common stock par value $0.005 per share by James Antal, the corporate stakeholder, on 19th of March 2021. This event was filed by Cleveland Biolabs Inc with SEC on 2013-03-18. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

An Additional Perspective On Cleveland Biolabs

The current price rise of Cleveland Biolabs could raise concerns from stockholders as the firm it trading at a share price of 6.16 on very low momentum in volume. The company directors and management may have good odds in positioning the firm resources to exploit market volatility in May. The stock standard deviation of daily returns for 30 days investing horizon is currently 7.49. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Cleveland Biolabs partners.

Margins Breakdown

Cleveland profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Cleveland Biolabs itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Cleveland Biolabs profit margins.
Operating Margin(68.01)
EBITDA Margin(9.31)
Gross Margin0.89
Profit Margin(9.36)


Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization USD is nearly stable at the moment. Cleveland Biolabs Average Assets is nearly stable at the moment. Additionally, Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization EBITDA is increasing over the last 8 years. Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The current value of Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization USD is -2,575,459. Cleveland Biolabs Average Assets is nearly stable at the moment. Additionally, Cleveland Biolabs Earnings Before Interest Taxes and Depreciation Amortization EBITDA is nearly stable at the moment.

Over 3 percent rise for Cleveland Biolabs. What does it mean for stockholders?

The skewness is down to -0.44 as of today. Cleveland Biolabs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cleveland Biolabs independently to ensure intended market timing strategies are aligned with expectations about Cleveland Biolabs volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Cleveland Biolabs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Cleveland Biolabs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on Cleveland Biolabs

While some other entities under the biotechnology industry are still a bit expensive, Cleveland Biolabs may offer a potential longer-term growth to stockholders. The bottom line, as of the 2nd of April 2021, we believe that at this point, Cleveland Biolabs is risky with high probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be overvalued. Our primary 30 days 'Buy-vs-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of Cleveland Biolabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com